Form 4: Repligen Corp Director Konstantin Konstantinov Reports Stock Option Grant and Restricted Stock Unit Award

Konstantin Konstantinov, a director at Repligen Corp, reported the acquisition of stock options and restricted stock units in a recent SEC filing.

Summary

• On May 15, 2025, Konstantin Konstantinov, a director of Repligen Corp, reported transactions involving Repligen Corp [RGEN] securities.
• Konstantinov was awarded 973 restricted stock units, each representing a contingent right to receive one share of Repligen Corporation's Common Stock.
• These restricted stock units vest on the earlier of May 15, 2026, or the date of the next annual meeting of the Company's shareholders.
• Konstantinov also acquired 1,800 stock options with an exercise price of $123.26, exercisable beginning May 15, 2026, and expiring on May 15, 2035.
• Following the reported transactions, Konstantinov directly owns 1,800 derivative securities and 2,894 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a common practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of stock options and restricted stock units is tied to future dates.

Industry Context

Stock option and restricted stock unit grants are common practices in the biotech industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and restricted stock units to align management's interests with shareholder value.
• The vesting schedules, typically ranging from one to four years, are also consistent with industry norms.

Stakeholder Impact

• Shareholders: Aligns director's interests with company performance.
• Employees: May boost morale knowing leadership is incentivized to improve company value.

Next Steps

• The restricted stock units will vest on the earlier of May 15, 2026, or the date of the next annual meeting of the Company's shareholders.
• The stock options become exercisable on May 15, 2026.

Key Dates

Keywords

Repligen Corp, Konstantin Konstantinov, stock options, restricted stock units, Form 4, insider trading, RGEN, director